

The Scars

by **Philip Carobot**
Consultant in GU Medicine
GU Clinic, Boffa Hospital

Sexually Transmitted Infections (STIs) are very common, with an estimated 330 million new cases yearly. They are the cause of serious morbidity (e.g. pelvic inflammatory disease, tubal infertility and ectopic pregnancies), as well as congenital and neonatal complications and even death. WHO estimates that, in Malta there could be up to 13,000 new cases per year, but this remains speculative.

This short report summarises the STIs and related conditions, seen in 2005 at the GU Clinic. This, of course, cannot be extrapolated to gauge any trends in the country as a whole and should not be interpreted as such. We need national prevalence studies for this information.

There were a total of 1832 attendances, a 15% increase over 2004. 74% were new patients, in keeping with the clinic's policy of offering follow-up visits only if strictly indicated. More time can then be thus dedicated to new cases.


174 of the new patients were non-residents. The male:female ratio was 1.6:1. The female attendances have gradually increased over the years, compared to a preponderance of males (M: F 2.3:1) in 2000.

Patient self-referral remains the most popular at 78% of the total. Caritas referrals account for 4.6% and doctor referral remains low at 16.8% (precisely the percentage for 2004).

As to sexuality 89% were heterosexual, 8% MSM (men who have sex with men) and 3% bisexual. Only one patient admitted to being lesbian.

The young (13-25 years) remain a significant group accounting for 48%. The youngest patient was 13 years old and the oldest was 78.

Total attendances 2000-2005



15.8% of heterosexuals admitted to having anal sex, at least occasionally, whereas 89% of MSM performed anal sex regularly.

The failure to attend rate was 21%. GU patients are well known to expect prompt consultation, and do not keep appointments considered to be too long. Ideally patients should not wait for more than 48 hours for an appointment. Urgent cases are seen within 48 hours. These are:

1. males with a urethral discharge;
2. males and females with genital ulcers;
3. patients 16 years old and younger, (especially if female);
4. if pregnant;
5. victims of sexual assault.


1. CHLAMYDIA

Globally *Chlamydia trachomatis* is the most prevalent sexually transmitted bacterial infection. Approximately 70% of the infections in women and 50% in men are asymptomatic or subclinical.

Up to 2003 testing was done with an EIA, which has well known limited sensitivity and specificity. 2004 saw the introduction of PCR testing which is much more accurate.


The GU Clinic report of 2004 expressed concern about the seemingly low numbers of chlamydia positives which coincided with the introduction of NAAT.

The 43 cases diagnosed in 2005 are a significant increase over 2004.



Chlamydia positives 2000-2005

On the other hand there were 209 cases of non-specific urethritis (NSU) and 129 cases of muco-purulent cervicitis (MPC). Chlamydia should be the cause in 30-50% of NSU and 25-45% of MPC. However in our patients the rate of chlamydia positivity was 11% and 0.2% respectively. We are therefore either over-diagnosing non-specific infection or under-diagnosing chlamydia. The problem highlighted in 2004 persists.



Non-specific infection 2000-2005 (NSU: non-specific urethritis, MPC: muco-purulent cervicitis,)


2. GONORRHOEA

There were 23 cases of gonorrhoea diagnosed; 20 in males and 3 in females. Although the actual total is small there has been an increase of 28% over 2004. The number almost certainly does not reflect the national prevalence. Many, if not most, of patients with acute symptoms, both male and female, are treated by other practitioners with broad-spectrum

of Venus

antibiotics and without investigations. Many patients attend the clinic having already had different antibiotics often prescribed, but also bought over the counter.

Of concern are that 4 cases of the 23 (17%) were resistant not only to penicillin but also ciprofloxacin which is the current first line treatment. First line treatment is dependent on the premise that more than 95% of the local strains are sensitive to it. The numbers are too small to suggest changing treatment policy, but we do need national prevalence studies to evaluate the true state of affairs.




Gonorrhoea 2000-2005

3. SYPHILIS

With the safer sex practises brought about by the fear of AIDS, syphilis had become almost extinct in the mid-1980's. However human nature being what it is, and people becoming complacent about HIV disease, mistaking the advances in

treatment for a cure, all acute STIs especially syphilis have made a dramatic come-back reaching epidemic proportions in Eastern Europe, but not confined there. In 2002 the U.K. reported a 73% increase in males and 33% in females.

In Malta there were only 3 cases of syphilis diagnosed in the 25 years, (and none for the 15 years), before the year 2000. The situation has changed.




Cases of syphilis 2000-2005

Cases of syphilis rose by 80% (from 10 cases in 2004 to 18 cases in 2005). 14 cases were early disease and therefore infectious, while the other 4 were late and by definition probably not. While 4 patients were non-Maltese they were all permanent residents.

Of note is one patient who was also HIV positive. Contact tracing could only be done with 3 patients.

continues on page 20

For the fracture protection
your patient needs



Actonel Once a Week 35mg film-coated tablets

ABBREVIATED PRESCRIBING INFORMATION:
PRESENTATION: ACTONEL film-coated tablets contain the equivalent of 32.5mg risedronate sodium. **INDICATIONS:** 35mg: Treatment of established postmenopausal osteoporosis, to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis, to reduce the risk of hip fractures. **DOSEAGE AND ADMINISTRATION:** 35mg: once a week orally. Take Actonel (35mg): at least 30 minutes before the first food, other medicinal product or drink (other than plain water) of the day. Do not suck or chew the tablets. Actonel is to be taken while in an upright position with a glass of plain water (≥ 120 ml). Do not lie down for 30 minutes after taking Actonel. **Children:** Safety and efficacy has not been established in children and adolescents. **CONTRAINDICATIONS:** Known hypersensitivity to risedronate or to any of its excipients, hypocalcaemia, pregnancy and lactation, severe renal impairment (creatinine clearance < 30 ml/min). **PRECAUTIONS:** This medicine contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Foods, drinks (other than plain water) and medicinal products containing polyvalent cations (such as calcium, magnesium, iron and aluminium) may interfere with the absorption of Actonel. Strict adherence to dosing recommendations is necessary. Caution should be used in patients who have a history of oesophageal disorders which delay oesophageal transit or emptying (e.g. stricture or achalasia) or who are unable to stay in the upright position for at least 30 minutes. Hypocalcaemia should be treated before starting therapy. Other disturbances of bone and mineral metabolism should be treated at the start of therapy. **INTERACTIONS:** No formal interaction studies have been performed, however no clinically relevant interactions with other medicinal products were found during clinical trials. Risedronate is not systemically metabolised. **USE IN PREGNANCY AND LACTATION:** Actonel must not be used during pregnancy or by breast feeding women. **SIDE EFFECTS:** The majority of undesirable effects observed in clinical trials were mild to moderate in severity. The following common adverse reactions were reported by the investigators as possibly or probably related to medicinal product in $\geq 1\%$, $< 10\%$ of patients and at an incidence greater than placebo in placebo controlled trials of Actonel 5mg, or in $\geq 1\%$, $< 10\%$ of patients in trials of 35mg vs 5mg: constipation, dyspepsia, nausea, gastrointestinal disorder, abdominal pain, diarrhoea, musculoskeletal pain, headache and body pain. The following adverse reactions associated with bisphosphonates were reported by the investigators as possibly or probably medicinal product related in $\geq 0.1\%$, $< 1\%$ of patients with Actonel 5mg or Actonel 35mg: gastritis, oesophagitis, dysphagia, oesoditis, oesophageal ulcer. Reported rarely ($\geq 0.01\%$, $< 0.1\%$) oesophageal stricture, glossitis. Intra. was uncommon ($\geq 0.1\%$, $< 1\%$) in clinical trials. Early, transient, asymptomatic and mild decreases in serum calcium and phosphate levels have been observed in some patients. Reported rarely: abnormal liver function tests. Very rare ($< 0.01\%$): hypersensitivity and skin reactions, including angioedema, generalised rash, and bullous skin reactions, some severe. **PACK QUANTITY:** 35mg: 4 tablets. **MARKETING AUTHORISATION NUMBERS:** 35mg: MA082/00103 **LEGAL CATEGORY:** POM **MARKETING AUTHORISATION HOLDER:** AVENTIS PHARMA AEBE, 2, A. Nicolou Str., 17671 Athens, Greece

MT.RIS.06.05.02



Adult immunisation – an overview

continued from page 4

Some would recommend meningococcal vaccine as well, especially in persons over 25 years of age and university attendees. BCG is not usually recommended to persons aged over 16 years as the data for its effectiveness is not available. However, it may be recommended to high risk groups where risk of exposure is high.

Travel related immunisations have increased in proportion with travel to areas at risk of specific infections. This is especially important in travel to Africa, South-East Asia and South America but not exclusive to these areas. Some travellers to forests in Northern Europe for example, may need cover for tick-borne encephalitis. It is thus important to consult the latest travel advice according to the destination and planned activities in that country.

The challenges of the future include vaccines for HIV and hepatitis C. Up till now, these remain elusive, although graded successes are recorded in both fields. One of the latest HIV vaccines on trial showing promise uses a disabled form of an adenovirus to ferry three specific HIV genes into the body. Other organisms being targeted include malaria and leishmania, now that both their genomes have been sequenced.

Some vaccines may protect against tumour development. The most well known is hepatitis B vaccine protecting against hepatoma. Other potential targets include papilloma virus, Epstein-Barr virus, and human T-cell lymphotropic virus I and II. Vaccines against diseases which are non-communicable, like Alzheimer's disease,

have also shown some promising results in animal studies. ☐

Bibliography

1. Disease Surveillance Unit. Annual Report 2003. Department of Public Health, Malta.
2. Immunisation against Infectious Diseases (the 'Green Book') 2006. Department of Health UK.
3. Ada G. Advances in immunology: Vaccines and Vaccination. N Engl J Med 2001; 345:1042-53.
4. Vaccination of Individuals with Uncertain or Incomplete Immunisation Status 2004. UK Health Protection Agency, Immunisation Department.

The Scars of Venus

continued from page 17

Details of VDRL/TPHA serology (2004 cases)

Patient	VDRL	TPHA
1	1:32	1:2560
2	Negative	1:320
3	Negative	1:160
4	Negative	1:320
5	Negative	1:80
6	Negative	1:320
7	1:8	1:5120
8	1:8	1:40960
9	1:16	1:40960
10	1:4	1:40960

It is still common practice to screen for syphilis with only a VDRL. This can often be negative, in both early as well as late disease. The international guidelines are to use VDRL and TPHA/or EIA. The VDRL, when positive is useful to monitor treatment.


5 of the patients had a persistently negative VDRL, and the diagnosis would have been missed.

Clinicians need to be made aware of the reappearance of this insidious disease, and to screen appropriately.

4. ANO-GENITAL WARTS


There were 145 cases of ano-genital warts which is a 32% increase over 2003.

Ano-genital warts (first presentation) continue to be a significant proportion of the total number of diagnoses (14%). The increase over the years has been maintained,



Ano-genital warts 2000-2005

Genital warts are associated with other significant pathology in 22% of cases. In this series the following additional (and unsuspected) conditions were found.



Ano-genital warts- associated pathology

This again highlights the importance of fully screening all new presentations of genital warts, before embarking on ablative therapy.

Part II will be published in the next issue

TheSynapse